Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy - PubMed
5 hours ago
- #lipid management
- #cost-effectiveness
- #cardiovascular disease
- Apolipoprotein B (apoB) is superior to LDL-C and non-HDL-C for assessing residual cardiovascular risk in patients on lipid-lowering therapy.
- An economic model showed using apoB goals for guiding therapy intensification is cost-effective, with an incremental cost-effectiveness ratio of $30,300 per QALY gained.
- Compared to non-HDL-C goals, apoB goals gained 1,324 QALYs but increased costs by $40.2 million.
- At a $120,000 per QALY threshold, apoB was optimal in 65% of analyses, while non-HDL-C was optimal in 25%.
- Higher costs with apoB are due to longer life expectancy and extended preventive treatment, not the test cost.